Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Shares rose in response to news that a large investment management company has purchased a significant ownership position.
Shares of Aptinyx (APTX +0.00%), a clinical-stage biotech focused on the brain and nervous system, rose about 27% on Friday.
The double-digit jump appears to be linked to the filing of an SEC document that shows that Adams Street Partners -- an investment management company with $40 billion in assets -- has acquired more than 5 million shares of Aptinyx's stock. That position represents more than 11% of shares outstanding.
Image source: Getty Images.
Traders bid up the share price in response to the big vote of confidence from Adams Street Partners.
Aptinyx's pipeline boasts three drugs that are in phase 2 development as possible treatments for diabetic neuropathy, fibromyalgia, post-traumatic stress disorder, and Parkinson's disease. These are all big indications with huge unmet medical needs, so success in any of them would be a financial windfall for Aptinyx. Adams Street Partners clearly believes that Aptinyx's pipeline holds a lot promise.
It's still unclear whether any of Aptinyx's drugs will make it to market, which is exactly why investing in clinical-stage biotechnology stocks is so difficult. Given the risks, my plan is to follow Aptinyx with great interest from the safety of the sidelines.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-28 19:25:07.326603.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
